Loading organizations...
§ Private Profile · Warren, NJ, USA
Roka Bioscience is a technology company.
Roka Bioscience develops and commercializes advanced molecular diagnostic testing solutions designed for the food safety industry. The company offers its proprietary Atlas System, an automated platform that performs rapid and accurate detection of foodborne pathogens. This system integrates ribosomal RNA (rRNA) targeting with key technologies such as Target Capture, Transcription-Mediated Amplification (TMA), and Hybridization Protection Assay (HPA) to provide highly sensitive and specific results with reduced enrichment times.
The company was established in 2009 by Paul G. Thomas, emerging as a spin-off from Gen-Probe, later acquired by Hologic. This strategic separation allowed Roka Bioscience to focus specifically on industrial testing assets and technologies, building upon existing innovations to address critical needs within the food production chain. Thomas led the company with an insight into the necessity for more efficient and dependable pathogen detection methods beyond traditional laboratory techniques.
Roka Bioscience serves a broad spectrum of clients within the food processing sectors, including producers of beef, dairy, poultry, produce, and pet food, along with environmental testing applications. The company’s vision centers on enhancing global food safety by equipping food manufacturers with advanced tools for detecting harmful microorganisms quickly and reliably, thereby safeguarding public health and maintaining product integrity in the marketplace.
Roka Bioscience has raised $68.0M across 2 funding rounds.
Roka Bioscience has raised $68.0M in total across 2 funding rounds.
Roka Bioscience has raised $68.0M in total across 2 funding rounds.
Roka Bioscience's investors include Aisling Capital, OrbiMed, Josh Bilenker, New Enterprise Associates, TPG Biotech, Gen-Probe.
Roka Bioscience is a molecular diagnostics company that develops and commercializes rapid, automated assay systems for detecting foodborne pathogens, primarily through its Atlas® System. It serves food processors, third-party testing labs, and government regulators by providing tests for pathogens like Salmonella, Listeria, E. coli O157:H7, and Shiga toxin-producing E. coli, solving the critical problem of slow, inaccurate traditional testing amid rising food safety demands and outbreak risks.[1][2][4][5] The company's fully automated platform offers walk-away convenience, reduced enrichment times, and superior sensitivity via ribosomal RNA (rRNA) targeting, helping manufacturers mitigate recalls, protect brands, and improve lab efficiency.[1][3][5]
Roka Bioscience was established in 2009 as a spin-off from Gen-Probe’s (now Hologic) industrial testing assets, gaining exclusive licensing rights to proven nucleic acid technologies like Target Capture, Amplification, and Hybridization Protection Assay.[2][4][6] Headquartered in Warren, New Jersey, it emerged to adapt Hologic's human diagnostics expertise—used for disease screening and blood tests—to the food safety sector, addressing urgent needs driven by high-profile pathogen outbreaks and consumer concerns.[2][4] Early focus centered on the Atlas System, delivering initial traction through automated molecular solutions that outperformed legacy methods in speed and accuracy.[1][5]
Roka Bioscience rides the trend of molecular diagnostics shifting to food safety, fueled by stricter regulations, frequent outbreaks (e.g., E. coli, Listeria), and consumer demand for traceable supply chains. Timing aligns with post-2009 growth in automated testing, as traditional culture methods lag behind real-time needs amid global food trade expansion.[2] Market forces like brand protection imperatives and lab efficiency pressures favor its solutions, influencing the ecosystem by enabling faster pathogen detection that reduces economic losses from recalls and sets standards for automation in agrotech diagnostics.[1][2][4]
Roka's trajectory points to expanded assay portfolios (e.g., more Campylobacter variants) and potential platform integrations for broader environmental monitoring, capitalizing on automation trends in food safety tech.[5] Rising AI-enhanced diagnostics and regulatory pushes for rapid testing will shape its path, potentially amplifying influence through partnerships with global manufacturers. As molecular tools become table stakes, Roka's Hologic-backed foundation positions it to lead in mitigating outbreak risks, echoing its origin as a pivotal spin-off delivering precision where delays cost brands dearly.[1][2]
Roka Bioscience has raised $68.0M across 2 funding rounds. Most recently, it raised $48.0M Series D in January 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2012 | $48.0M Series D | Aisling Capital, OrbiMed, Josh Bilenker, New Enterprise Associates, TPG Biotech | |
| Jul 1, 2011 | $20.0M Series C | OrbiMed, Gen-Probe, New Enterprise Associates, TPG Biotech |